Alpha Centric Advisors LLC Adc Therapeutics Sa Transaction History

Alpha Centric Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.72 - $2.37 $209,136 - $688,409	290,468 Added 37.34%	1,068,468 $961,000
Q2 2023 Aug 08, 2023	BUY	$1.9 - $2.66 $34,200 - $47,880	18,000 Added 2.37%	778,000 $1.67 Million
Q1 2023 May 12, 2023	BUY	$1.92 - $5.45 $888,000 - $2.52 Million	462,500 Added 155.46%	760,000 $1.48 Million
Q4 2022 Feb 07, 2023	BUY	$2.87 - $5.24 $853,825 - $1.56 Million	297,500 New	297,500 $1.14 Million
Q3 2021 Mar 09, 2022	SELL	$20.45 - $30.0 $531,700 - $780,000	-26,000 Closed	0 $0
Q2 2021 Mar 09, 2022	BUY	$20.38 - $27.04 $183,420 - $243,360	9,000 Added 52.94%	26,000 $633,000
Q1 2021 Mar 09, 2022	BUY	$22.75 - $34.05 $307,125 - $459,674	13,500 Added 385.71%	17,000 $415,000
Q4 2020 Mar 11, 2022	BUY	$25.26 - $38.02 $63,150 - $95,050	2,500 Added 250.0%	3,500 $112,000
Q3 2020 Mar 11, 2022	BUY	$32.87 - $51.05 $32,870 - $51,050	1,000 New	1,000 $33,000

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $172M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.